iCell Microglia

Access iCell^® Microglia: the only iPSC-derived microglia cells available that are based on technology developed by the Blurton-Jones Laboratory (Abud et al., Neuron 2017). iCell Microglia offer researchers unprecedented reproducibility and efficiency for modeling neurodegenerative diseases.

As the primary immune cells of the central nervous system (CNS), microglia play crucial roles in neural homeostasis and neurodegeneration. iPSC-derived microglia overcome the limited availability and inconsistency associated with primary human microglia, providing a robust and reliable in vitro model for studying human microglial cells. Use iCell Microglia to streamline high-quality research across neurological development, health, and disease.

• Consistent excellence Rigorous quality control processes and a highly pure population of iPSC-derived microglia ensure reproducible results with every batch.
• Human relevance iCell Microglia express relevant microglial cell markers, including TMEM119, P2RY12, IBA1, CX3CR1, and TREM2.
• Physiological function Like primary human microglia, iCell Microglia are capable of phagocytosis, cytokine signaling, and regulating synaptic plasticity.
• Disease modeling iCell Microglia from an Alzheimer’s cohort (APOE 4/4 or TREM2 R47H genotype) and engineered TREM2 variant models (heterozygous or knockout) facilitate vital neurodegeneration research.
• Simple implementation Cryopreserved iCell Microglia arrive fully differentiated, enabling more experiments in less time and allowing co-culture with other iPSC-derived cells.